Skip to main content
. 2017 Jan 4;8(7):11173–11186. doi: 10.18632/oncotarget.14491

Figure 3. MDR3 and MRP1 immunohistochemical analysis expression in 31 WT patients from Tissue MicroArray.

Figure 3

(A) Immunohistochemical detection of MDR3 and MRP1 in kidney and intermediate and high-risk WT (20× and 40× amplification). High-risk tumours showed a stronger expression of MDR3 and MRP1 than kidney and intermediate-risk tumours. (B) Significant correlation between negative and positive expression of MDR3 and MRP1 in intermediate- and high-risk WT samples.